Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269251 | 0.98 | LMNA (0.43) | LMNAHRH3CYP1A2NAAAMAPT | |
| SCHEMBL3997403 | 0.87 | HRH3 (0.50) | LMNAHRH3CYP1A2NAAAMAPT | |
| SCHEMBL4002648 | 0.85 | HRH3 (0.54) | LMNAHRH3CYP1A2NAAAMAPT | |
| SCHEMBL31528856 | 0.84 | HRH3 (0.46) | LMNAHRH3CYP1A2NAAAMAPT | |
| SCHEMBL3997328 | 0.83 | HRH3 (0.50) | LMNAHRH3NAAAMAPTALDH1A1 | |
| SCHEMBL15269270 | 0.80 | TRPA1 (0.39) | LMNACYP1A2NAAAALDH1A1TRPA1 | |
| SCHEMBL838431 | 0.78 | CYP1A2 (0.51) | CYP1A2NAAAMAPTALDH1A1POLB | |
| SCHEMBL23465178 | 0.74 | LMNA (0.44) | LMNAHRH3CYP1A2MAPTALDH1A1 | |
| SCHEMBL23342769 | 0.72 | CYP1A2 (0.42) | LMNAHRH3CYP1A2MAPTALDH1A1 | |
| SCHEMBL18912059 | 0.70 | NAAA (0.44) | HRH3CYP1A2NAAACARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084759-A1 | FLUORESCENT DYE OIL TRACER COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2025-03-13 | — | — | US | claimed |
| US-20240409995-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING THROUGH MOLECULAR BARCODING AND EX-SITU ANALYSIS | GLYPHIC BIOTECHNOLOGIES, INC. | 2024-12-12 | — | — | US | claimed |
| EP-3383378-B1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2024-04-17 | — | — | EP | claimed |
| EP-3383376-B1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2021-05-12 | — | — | EP | claimed |
| EP-3383376-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | The Procter and Gamble Company (US) | 2018-10-10 | — | — | EP | claimed |
| EP-3383378-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | The Procter and Gamble Company (US) | 2018-10-10 | — | — | EP | claimed |
| CN-108601754-A | Inhibit carnitine to trimethylamine（TMA）The method of conversion | 宝洁公司 | 2018-09-28 | — | — | CN | claimed |
| WO-2017095995-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2017-06-08 | — | — | WO | claimed |
| WO-2017095993-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2017-06-08 | — | — | WO | claimed |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | claimed |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | claimed |
| WO-2011066864-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2011-06-09 | — | — | WO | claimed |
| US-20260049991-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | GLYPHIC BIOTECHNOLOGIES INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12517133-B2 | Macromolecule analysis employing nucleic acid encoding | DF PEPTIDE ACQUISITION LLC | 2026-01-06 | — | — | US | disclosed |
| EP-4655289-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | Glyphic Biotechnologies, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-6153634-A | FOR THERAPY AND PROPHYLAXIS OF CANCER TUMORS; INHIBITOR OFCYCLIN-DEPENDENT KINASES (CDKS) | HOFFMANN-LA ROCHE INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-2000035920-A2 | 4,5-AZOLO-OXINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| EP-1001974-A1 | 4-AMINO-PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006434-A1 | 4-AMINO-PHENYLALANINE TYPE COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049991-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING USING GUANIDINYLATING AGENTS | CHAMP1, S100A11, TFIP11 | LMNA 949/4885HRH3 4186/4885CYP1A2 4827/4885 |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | HNMT, BHMT, PNMT | LMNA 2671/4885HRH3 131/4885CYP1A2 1854/4885 |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | CRAT, CPT1A, CPT1B | LMNA 994/4885HRH3 888/4885CYP1A2 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.